Bio/Pharmaceutical Analysis Techniques

Laboratory Equipment and Instruments

Analytics

Data and Artificial Intelligence

Inhalation Drugs

Parenterals and Injectables

Solid/Semi-Solid Dosage

Specialty Dosage Drugs

Dosage Forms

APIs and Excipients

Formulation and Drug Delivery

Ingredients

Intellectual Property and Patents

Process and Scaling

Drug Development

Aseptic/Sterile Processing

Equipment

Manufacturing, Biologic Drugs

Manufacturing, Biosimilars and Biobetters

Manufacturing, Cell Therapies

Manufacturing, Gene Therapies

Manufacturing, Inhalation Drugs

Manufacturing, Parenterals and Injectables

Manufacturing, Solid and Semi-Solid Dosage Drugs

Packaging and Distribution

Process and Automation

Supply Chain

Manufacturing

Contract Analytical Services

Contract Development Services

Contract Manufacturing Services

Contract Research Services

Logistics and Distribution

Regulatory Consulting

Outsourcing

Ask the Expert

Quality Assurance/Quality Control

Regulatory Oversight and Compliance

Quality Systems

News

Business

Bio/Pharma Business

All News

Bio/Pharma News

Publications

All Publications

PharmTech

PharmTech Europe

Resources

Marketplace

ICH Q9 Revision: A Comprehensive Resource on Quality Risk Management

Peer-Reviewed Research

PharmTech Products

Pharma Insights

Whitepapers

Webcasts

Multimedia

All Videos

Behind The Headlines

Drug Digest Videos

Drug Solutions Podcast

Conferences

Conference Coverage

Conference Listing

Subscribe

Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and expert industry news.

About Us

Advertise

Contact Us

Editorial Info

Editorial Advisory Board

Do Not Sell My Personal Information

Privacy Policy

Terms and Conditions

Pharmaceutical Technology - Pharma News and Development Insights

Twitter

LinkedIn

Spotlight

Topic

COVID-19 Update

APIs

Analytical Method Development

Aseptic Processing

Biologic Drugs

Drug Delivery

Excipients

Formulation

Packaging

Process Control/PAT

Process Development

QA/QC

Regulatory Action

1rem

In the conclusion of this three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

What’s Reasonable to Expect from Agentic AI in Pharma? Part Three: Tapping Agentic AI’s Potential

In this continuation of a three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

What’s Reasonable to Expect from Agentic AI in Pharma? Part Two: Agentic AI’s Adoption in Life Sciences

Advances in digital technologies offer effective data handling for bio/pharma manufacturing.

Optimizing Data Use for Digital Transformation

In a three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

What’s Reasonable to Expect from Agentic AI in Pharma? Part One: The Evolution of AI

Survey responses indicate that bio/pharma faces tariff-driven rising costs and supply strain, with firms aiming to boost compliance and diversification and seeking stable trade and R&D support.

Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results

 Benjamin McLeod and Sebastian Lykke Skafte Andersen go behind the headlines to examine the motivations behind recent M&A activity, tariff responses, and more.

Behind the Headlines, Episode 23: Patent Cliff Deals, Tariff Pressures, and the In Vivo Cell Therapy Bet

 is a bi-weekly panel discussion examining the latest trends, readouts, and other factors that drive pharmaceutical news and innovation. Each episode features consultants, venture capitalists, scientists, patient advocates, and journalists discussing the prior weeks’ top news while seeking to highlight the more enduring lessons that hide behind the headlines.

In episode 23, the panel analyzes how looming patent cliffs, rising trade pressures, and a new wave of in vivo platforms are reshaping the biotech deal landscape. Benjamin McLeod, founder of Convey BIO, and Sebastian Lykke Skafte Andersen, managing director and founder of ClarityNorth Partners, examine how recent headlines signal deeper structural shifts for pharma commercialization and manufacturing strategy.

The panel begins by spotlighting Merck’s $10 billion acquisition of Verona Pharma (1) as a clear example of dealmaking driven by pricing headwinds. With the 

Most-Favored Nation (MFN) executive order

 pushing U.S. drug prices toward European benchmarks, biopharma buyers are racing to acquire late-stage, revenue-generating assets ahead of price compression. As margins come under threat, preemptive M&A is becoming a go-to strategy for portfolio fortification.

In Vivo CAR-T Moves Closer to Center Stage

Attention then turns to the in vivo cell therapy frontier. Gilead’s Kite Pharma recently acquired Interius Biotherapeutics for $350 million (2), adding a modular in vivo CAR-T platform aimed at broadening therapeutic applications and improving scalability. Cindy Perettie, executive vice president at Kite, highlighted the potential for combining Interius’ novel platform with Kite’s established infrastructure to accelerate in vivo therapeutic development.

AstraZeneca’s massive $50 billion U.S. investment

 as a strategic response to escalating U.S. 

, some exceeding 250%. The company’s pivot marks a larger industry trend toward reshoring biomanufacturing as a form of industrial policy, not just portfolio strategy. Beyond portfolio diversification, AstraZeneca’s U.S. expansion includes GLP-1 pipeline growth, CGT infrastructure, and regulatory optimization through increased U.S.-based trials.

Watch the full episode above for more insights into the evolving biopharma landscape and catch up on previous episodes of 

References 
1. Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade. Press Release. Merck. July 9, 2025. https://www.merck.com/news/merck-to-acquire-verona-pharma-expanding-its-portfolio-to-include-ohtuvayre-ensifentrine-a-first-in-class-copd-maintenance-treatment-for-adults-and-expected-to-drive-growth-into-the-next-dec/
2. Kite to Acquire Interius BioTherapeutics to Advance In Vivo Platform. Press release. InteriusBioTherapeutics. August 21, 2025. https://interiusbio.com/press-release/kite-to-acquire-interius-biotherapeutics-to-advance-in-vivo-platform/

Videos

PharmTech News

Behind the Headlines

PharmTech Videos

In an interview with Pharmaceutical Technology®, Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.

Industry Outlook 2025: Continuing Innovation 

Looking at 2024, Michelle Bridenbaker, COO of Unbiased Science—a health science communications company—believes the most noteworthy trend shaping the bio/pharma industry has been the level of innovation that has been seen. “The first area that I really see that has been consequential has been the advances we’ve made in kind of personalizing medicine,” she says. “So, this is everything from our ability to do DNA sequencing, to RNA technology, CRISPR [clustered regularly interspaced short palindromic repeats], even things that are more lab and bench work in organoids.”

Of course, adding to this trend is artificial intelligence (AI), Bridenbaker continues, which is allowing for greater analysis of data. “There’s no question that AI is also impacting [personalized medicine], because we’re catching patients [that we previously missed],” she asserts. “I work in the rare disease space, and we missed patients before, but now, we can use AI to look at data that already exists and pick out that one patient that we may not have caught before, that needle in the haystack.”

Moving into 2025 and beyond, Bridenbaker anticipates a continuation in innovation and use of AI. “In 2025 and beyond, I really feel that we are going to have to spend a lot of time educating and upskilling our workforce,” she stresses. “And I think this is sometimes underestimated. It's like, the technology is great and it's wonderful, we're implementing it, but I think as well, we have to make sure we have the requisite skills to be able to keep up with the technology.”

Michelle Bridenbaker, BSN, MBA, MS, is COO of Unbiased Science—a health science communications company. She is also the Vice-President of the Medical Information Leaders in Europe, and she heads up the Global Medical Information and Communications function at Recordati Rare Diseases. Michelle has approximately 20 years’ experience within industry, working across a variety of roles. Most recently, she has been involved in trying to help shape the future and strategy for the pharmaceutical industry to be more effective communicators.

Business News

Regeneron’s Bari Kowal gave insight into how the biopharma industry views the application of AI in R&D.

Exploring the use of AI in R&D at the US Pharma and Biotech Summit

® at the US Pharma and Biotech Summit, Regeneron's Bari Kowal, senior vice-president, head Development Operations & Portfolio Management, talked about the implementation of artificial intelligence (AI) in the R&D space. For example. Regeneron, Kowal explained, has been using AI for quite some time. Though not a new technology, she observed, AI has allowed the company to leverage many large language models and advanced searches for the past few years. Because of this, the company has built up collections of data in different areas, such as in genomics, protein databases, or for operational uses, including patient populations, study-level data, information about investigators, and quality of documents, among others.

“[Much] of our work is crossing over multiple facets of the drug development lifecycle early on in the discovery space, looking at how we manufacture and improving those processes, but also really looking at how we execute trials and reach out to the patients create diversity in the populations,” Kowal said. “We utilize some of the genomic data for finding the targets and more personalized medicine. [There are many] ways that we're leveraging AI.”

However, she emphasizes that the real value of AI is the ability to use it for existing data, especially in the search for optimizing operational efficiency. “Looking in the future, how do we use this to help our decision making and really better predict molecules that will have a tremendous effect? The biggest benefit that I can see, at least today, is that operational efficiency. If we can streamline drug development, from start to finish, our mission is to bring important medicines to patients at the end of the day, and so the time it takes today for drugs to be developed is too long. It's not measured in years, it's measured in decades,” she remarked. “If we can go from the research space to the development space in [a] few years, that is so much better and more beneficial to the patients that are waiting for those treatments.”

While speaking on a panel at the summit about diverging schools of thought on how AI should be used in R&D, Kowal observed that there were not necessarily divergent views by the panelists on how to use AI, but rather that the panelists had like-minded views on the topic. “I think we all believe that AI can be transformative. I think we believe that, ultimately, we're scratching the surface of what AI can do, but we also understand the human component and the context of human intelligence that you have to apply,” she stated.

 occurred on May 16, 2024 in New York, NY.

Bari Kowal, senior vice-president, head Development Operations & Portfolio Management, Regeneron, discussed the utility of AI and how it can benefit R&D work.

NOINDEX

NOFOLLOW

Latest Conference

A Discussion on Using AI in R&D at the US Pharma and Biotech Summit

The management and analysis of vast data generated by advanced analytical technologies are revolutionizing the drug discovery and development process.

Drug Digest: The Rush for Quality Data and the Means to Protect It

In this episode of Drug Digest, industry experts discuss why data is the biopharma industry’s most valuable asset today. The discussion also delves into the means by which the industry as a whole is learning to upgrade data integrity practices to better protect their data and the use of innovative technologies, such as advanced graph technologies, to better shape the drug discovery and development process.

Nathalie Batoux, Product Manager, Research Innovation, IDBS

Nathalie Batoux left the lab and joined IDBS in 2005, driven by her passion to help scientists with workflows and informatics tools to expedite their research. At IDBS, Batoux is a product manager for Research and Innovation. In her role, she regularly interacts with customers and researchers to gain an understanding of their data management needs and drives the development of platform capabilities to provide a solution. Batoux is an organic chemist by training and started her career as a post-doctoral researcher in chemistry working in the domain of nucleoside and dinucleotide analogues.

Thierry Dorval, Head of Data Science & Data Management, Servier

Thierry Dorval received a PhD in image analysis and artificial intelligence (AI) from University Pierre & Marie Curie and then joined the institut Pasteur Korea in 2005 as a group leader specializing in high content screening applied to cellular differentiation and toxicity prediction. In 2012, he joined AstraZeneca, where he focused on developing and advising on quantitative image and data analysis solutions in support of high content phenotypic screening. In 2015 he joined Servier, France, to lead the Data Sciences & Data Management pole of activities where he is in charge of optimizing the early stages of the drug discovery process by taking advantage of cutting-edge computational approaches. This includes usage of AI, knowledge graph database, system modeling and sequences design applied to multiple modalities including small molecules, antibodies, and oligonucleotides.

Jeremy Grignard, Data & Research Scientist, Servier

Jeremy Grignard holds a PhD in computer science, data, and artificial intelligence (AI) from École Polytechnique. He also earned a master’s degree in applied mathematics in Data Science and an engineering degree in computer science and big data. In 2019, he joined the Servier Research & Development Institute to complete his thesis with Inria Saclay, during which he developed computational methods using knowledge graphs, data science, and mathematical modeling to improve early drug discovery. Since 2022, he has been designing and implementing AI projects related to gene inference, explainable machine learning, heteromodality algorithms, biologically constrained deep learning models, knowledge graphs, and large language models.

This episode of Drug Digest is sponsored by:

Drug Digest is a tech talk video series with the 

® editors, who interview industry experts to discuss the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products.

This discussion explores how the management and analysis of vast data generated by advanced analytical technologies are revolutionizing the drug discovery and development process within the biopharma industry.

Data and Artificial Intelligence

Latest News